Stocks · News reference

Reported Earlier, Anteris Secures German Regulatory Clearance To Expand PARADIGM Trial Comparing DurAVR THV With Commercial TAVRs Into Europe’s Largest TAVR Market

Oct 20, 2026, 5:15 AMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Fiscal.aiOct 27, 2026, 1:02 PM
Anteris Technologies Announces Upcoming Data Presentation for Medium-Size DurAVR THV at TCT 2026
Anteris Technologies will present the first 30-day clinical and hemodynamic outcomes for its medium-size DurAVR Transcatheter Heart Valve at the upcoming TCT 2026 conference.
AVR
Globenewswire IncOct 27, 2026, 10:00 AMNa
Anteris Announces Upcoming Data Release for Medium-Size DurAVR THV from EMBARK Study at TCT 2026
Anteris Technologies announced that it will present first 30-day clinical and hemodynamic outcomes for its medium-size DurAVR Transcatheter Heart Valve at the TCT 2026 conference in San Diego. The presentation will showcase results from the ongoing EMBARK study, which has treated over 130 patients with the DurAVR THV since 2021. The company will also feature a live case demonstration of the biomimetic valve technology.
AVR
BenzingaOct 14, 2026, 10:47 AMBenzinga Newsdesk
Cantor Fitzgerald Reiterates Overweight on Anteris Technologies Glb, Maintains $15 Price Target
Cantor Fitzgerald analyst Gabie Ingoglia reiterates Anteris Technologies Glb (NASDAQ:AVR) with a Overweight and maintains $15 price target.
AVR